The main focus of the research in our lab is trying to understand how genomic information is translated into gene regulation. A well-established view of transcriptional regulation is that proteins, such as site-specific DNA binding transcription factors and components of the general transcriptional machinery, bind to cis-regulatory elements (such as promoter and enhancer regions) to control the level of transcription of different genes.


In the past, the interaction of transcription factors with promoters and enhancers was studied using standard one-gene-at-a-time approaches. However, sequencing of the human genome has revealed a much more complex situation than previously considered. For example, we now know that the majority of human genes have more than one promoter region, that enhancers can function in an extremely cell type-specific manner, and that most transcription factors have highly related gene family members that all have very similar DNA binding domains (and thus have the potential to bind to the same or similar consensus motifs). Due to this increased complexity, we have moved our studies into genome-wide approaches that allow us to identify all the sites to which a transcription factor binds in the human genome.

We are currently extending our studies on enhancer binding proteins and also performing genome-wide analyses of C2H2 zinc finger transcription factors (the largest family of site-specific factors encoded in the human genome). Gene regulation is also controlled at the level of chromatin, a dynamic structure that is modified on both its DNA and protein components. The distribution of DNA and histone modifications throughout the genome is referred to as the epigenome. Unlike our genomic sequences that are the same in all cells of a given individual, we have hundreds of different epigenomes, with different cell lineages and differentiation states giving rise to unique chromatin structures. Therefore, a comprehensive study of gene regulation requires developing complete epigenomic profiles of the cell type in which a given transcription factor is being analyzed. As part of an NIH Roadmap Epigenome Mapping Center (see Nat Biotech 28: 1045, 2010), we are currently mapping the epigenomes of a variety of different primary human cell types. In addition, we are extending our studies to include analysis of the epigenomes of several disease states, before and after treatment with inhibitors of transcription factors and chromatin modifiers.